• Masaaki Hotta, Tomoki Ito, Akiko Konishi, Hideaki Yoshimura, Takahisa Nakanishi, Shinya Fujita, Atsushi Satake, and Shosaku Nomura.
• First Department of Internal Medicine, Kansai Medical University, Japan.
• Intern. Med. 2021 Jan 1; 60 (3): 463-468.

AbstractFew reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe a 45-year-old woman who had MM (diagnosed with IgA-κ type) with CNS relapse early after undergoing autologous hematopoietic stem cell transplantation. Because no standard treatment for CNS lesions of MM has been established, we conducted a literature review on the cerebrospinal fluid (CSF) transferability of drugs for MM, since it was considered to be a useful tool for CNS involvement. Immunomodulatory-drugs including pomalidomide exhibit a good CSF transfer ability, and, therefore, may be beneficial against the CNS involvement of MM.

15 keywords...

hide…